When it matters most, ClotChip® provides answers.

ClotChip® makes clinical evaluation of whole-blood coagulation radically more accessible, at the point of care.


ClotChip® leverages dielectric spectroscopy to assess
whole-blood coagulation in an innovative and advantageous way.


ClotChip® technology is agnostic to the cause of the coagulation defect. This elegant simplicity means ClotChip works across markets with no special reagents.


The Innovation and simplicity of ClotChip® deliver clinical utility in providing ready access to inform clinicians of patient clotting ability at the point-of-care.

Unlike existing global hemostasis assays that require intensive training and specialized equipment, ClotChip® is positioned to profoundly alter the evaluation and clinical management of bleeding risk by making coagulation evaluation more accessible than ever before.

ClotChip® is a class 2 medical device that has received FDA breakthrough device designation in March 2020 and is currently in clinical trials.